Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT00205478 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT00205478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00205478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
February 28, 2006
Enrollment
300
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis